Document Detail


Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
MedLine Citation:
PMID:  22293546     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.
Authors:
Catherine Fagard; Céline Colin; Charlotte Charpentier; Agathe Rami; Christine Jacomet; Patrick Yeni; Daniel Vittecoq; Christine Katlama; Jean-Michel Molina; Diane Descamps; Geneviève Chêne; Yazdan Yazdanpanah;
Related Documents :
22305646 - Functional outcomes following revascularisation for critical limb ischaemia.
19826176 - Rate of undesirable events at beginning of academic year: retrospective cohort study.
22670166 - Very early anthropometric changes after antiretroviral therapy predict subsequent survi...
18430196 - Predictors of mortality in hiv-infected patients starting antiretroviral therapy in a r...
18560556 - Evaluation of nutritional status of new tuberculosis patients at the effia-nkwanta regi...
17656176 - Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levono...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  59     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-13     Completed Date:  2012-04-23     Revised Date:  2013-08-26    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  489-93     Citation Subset:  IM; X    
Affiliation:
INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France. catherine.fagard@isped.u-bordeaux2.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Drug Resistance, Multiple, Viral / drug effects,  genetics
Female
Follow-Up Studies
HIV Infections / drug therapy*,  virology
HIV Protease Inhibitors / adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Pyridazines / administration & dosage,  adverse effects
Pyrrolidinones / administration & dosage,  adverse effects
RNA, Viral / analysis
Ritonavir / administration & dosage,  adverse effects
Sulfonamides / administration & dosage,  adverse effects
Chemical
Reg. No./Substance:
0/HIV Protease Inhibitors; 0/Pyridazines; 0/Pyrrolidinones; 0/RNA, Viral; 0/Ritonavir; 0/Sulfonamides; 0C50HW4FO1/etravirine; 22VKV8053U/raltegravir; YO603Y8113/darunavir
Investigator
Investigator/Affiliation:
J P Faller / ; H Aumaitre / ; P Chevojon / ; L Gerard / ; J M Molina / ; D Sereni / ; F Timsit / ; M Bentata / ; O Bouchaud / ; A Compagnucci / ; C Drobacheff / ; M Dupon / ; J M Ragnaud / ; J P Viard / ; J Gaillat / ; C Goujard / ; A Rami / ; G Pichancourt / ; P De Truchis / ; D Vittecoq / ; G Pialoux / ; F Boué / ; L Weiss / ; D Salmon-Ceron / ; Y Lévy / ; C Katlama / ; A Simon / ; D Bollens / ; J M Chennebault / ; P Morlat / ; F Jeanblanc / ; C Trepo / ; I Poizot-Martin / ; P Yeni / ; F Raffi / ; P Perré / ; J Durant / ; E Rosenthal / ; C Michelet / ; F Bastides / ; B Marchou / ; R Verdon / ; C Jacomet / ; L Piroth / ; P Leclercq / ; Y Yazdanpanah / ; M A Khuong / ; G Beck-Wirth / ; L Blum /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of patterns of three-phase bone scintigraphy for patients with complex regional pain syndro...
Next Document:  Analysis of a previously identified 'pain protective' haplotype and individual polymorphisms in the ...